Advances in Anticoagulation Therapy: The Role of Selective Inhibitors of Factor Xa and Thrombin in Thromboprophylaxis after Major Orthopedic Surgery

ABSTRACT

A new generation of antithrombotic agents that target a single enzyme within the procoagulant cascade is making its way into mainstream clinical practice. Borrowing selectively from the properties of their parent anticoagulant, unfractionated heparin, as well as from those of peptide anticoagulants from reptile or insect venoms, designers of the new drugs have created targeted inhibitors of thrombin, factor Xa, or other specific factors in the procoagulant pathways. These new agents promise efficacy and safety profiles far more favorable than those of conventional anticoagulants for thromboprophylaxis after major orthopedic surgery and require no laboratory monitoring of drug efficacy in this setting. Ximelagatran, the oral “prodrug” of the direct thrombin inhibitor melagatran, is in phase III of clinical development. Clinical trials using various dosages of ximelagatran, sometimes preceded by subcutaneous melagatran, as thromboprophylaxis after total hip or knee replacement surgery have suggested efficacy equal to or better than that of warfarin and enoxaparin. The best dosing regimen and optimal timing of first dose for melagatran and ximelagatran remain to be determined, as do the mechanism and impact of drug disturbance of hepatic function. Fondaparinux, a selective, synthetic inhibitor of factor Xa, has been shown in large clinical trials to be superior to low-molecular-weight heparins and is approved as a fixed once-daily subcutaneous 2.5-mg dose for thromboprophylaxis for hip or knee replacement surgery and after hip fracture repair. Fixed-dose fondaparinux 2.5 mg initiated 6 to 8 hours after surgery achieved superior efficacy and comparable safety in head-to-head comparisons with enoxaparin for the prevention of venous thromboembolism after major orthopedic surgery. Fondaparinux is the only agent approved for use in hip fracture patients in the United States at this time and has recently gained approval for extended prophylaxis in this patient population.

KEYWORDS

Thrombosis - thromboprophylaxis - orthopedic surgery - ximelagatran - fondaparinux - low-molecular-weight heparin

REFERENCES

• 1 White R H. The epidemiology of venous thromboembolism.  Circulation. 2003;  107(Suppl 1) 14-18
• 2 Geerts W H, Heit J A, Clagett G P et al.. Prevention of venous thromboembolism.  Chest. 2001;  119(Suppl 1) 132S-175S
• 3 American Public Health Association and Centers for Disease Control gather to elevate awareness of deep-vein thrombosis as major health threat. American Public Health Association. Available at: http://www.apha.org/news/press/2003/dvt.htm. Accessed August 14, 2003
• 4 Hirsh J, Dalen J E, Anderson D R et al.. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest. 1998;  114(Suppl 5) 445S-469S
• 5 Bristol-Myers Squibb. Package Insert: Coumadin^® (warfarin sodium tablets, USP), crystalline Coumadin^® for injection (warfarin sodium for injection, USP). Princeton, NJ; Bristol-Myers Squibb 2002
• 6 Summary of Information Submitted to MEDMARX^SM in the Year 2001: A Human Factors Approach to Medication Errors. Rockville, MD; US Pharmacopeia 2002
• 7 Hirsh J, Warkentin T E, Shaughnessy S G et al.. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.  Chest. 2001;  (Suppl 1) 64S-94S
• 8 Van Boeckel C A, Petitou M. The unique antithrombin-III binding domain of heparin: a lead to new synthetic antithrombotics.  Angew Chem Int Ed Engl. 1993;  32 1671-1690
• 9 Quader M A, Stump L S, Sumpio B E. Low molecular weight heparins: current use and indications.  J Am Coll Surg. 1998;  187 641-658
• 10 Hirsh J, Levine M N. Low molecular weight heparin.  Blood. 1992;  79 1-17
• 11 Warkentin T E. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.  Transfus Med Rev. 1996;  10 249-258
• 12 Pharmacia and Upjohn Package Insert: Heparin sodium injection, USP. Kalamazoo, MI; Pharmacia and Upjohn 2000
• 13 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  1330 1330-1335
• 14 Aventis Pharmaceuticals Package Insert: Lovenox^® (enoxaparin sodium injection). Bridgewater, NJ; Aventis Pharmaceuticals 2003
• 15 Pharmacia and Upjohn Package Insert: Fragmin^® (dalteparin sodium injection). Kalamazoo, MI; Pharmacia and Upjohn 2002
• 16 Pharmion Package Insert: Innohep^® (tinzaparin sodium injection). Boulder, CO; Pharmion 2003
• 17 Berlex Package Insert: Refludan^® (lepirudin [rDNA] for injection). Wayne, NJ; Berlex 2002
• 18 Aventis Pharmaceuticals Package Insert: Iprivask^® (desirudin for injection [15 mg]). Bridgewater, NJ; Aventis Pharmaceuticals 2003
• 19 The Medicines Co. Package Insert: Angiomax^® (bivalirudin) for injection. Parsippany, NJ; The Medicines Co 2002
• 20 GlaxoSmithKline Package Insert: Argatroban (injection). Research Triangle Park, NC; GlaxoSmithKline 2003
• 21 Eriksson U G, Bredberg U, Hoffmann K J et al.. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.  Drug Metab Dispos. 2003;  31 294-305
• 22 Bauer K A, Hawkins D W, Peters P C et al.. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.  Cardiovasc Drug Rev. 2002;  20 37-52
• 23 Paolucci F, Clavies M C, Donat F, Necciari J. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins.  Clin Pharmacokinet. 2002;  41(Suppl 2) 11-18
• 24 Lieu C, Shi J, Donat F et al.. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome p450-mediated metabolism of concomitant drugs.  Clin Pharmacokinet. 2002;  41(Suppl 2) 19-26
• 25 Ollier C, Faaij R A, Santoni A et al.. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers.  Clin Pharmacokinet. 2002;  41(Suppl 2) 31-37
• 26 Faaij R A, Burggraaf J, Schoemaker R C, Van Amsterdam R GM, Cohen A F. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.  Br J Clin Pharmacol. 2002;  54 304-308
• 27 Mant T, Fournié P, Ollier C, Donat F, Necciari J. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers.  Clin Pharmacokinet. 2002;  41(Suppl 2) 39-45
• 28 Peters P C, Nutescu E, Andersen J. Wound pharmacobiology.  Orthopedics. 2003;  26(Suppl 8) s837-842
• 29 Ahmad S, Jeske W P, Walenga J M et al.. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.  Clin Appl Thromb Hemost. 1999;  5 259-266
• 30 Organon Sanofi-Synthelabo LLC Package Insert. Arixtra^® (fondaparinux sodium injection). West Orange, NJ; Organon Sanofi-Synthelabo LLC 2003
• 31 The REMBRANDT Investigators . Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation.  Circulation. 2000;  102 2726-2731
• 32 The MATISSE Investigators . The MATISSE-DVT trial: a randomized, double-blind study comparing once-daily fondaparinux (Arixtra^®) with the low-molecular-weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep-vein thrombosis (DVT).  J Thromb Haemost. 2003;  1(Suppl 1) OC332
• 33 The MATISSE-PE trial . A multicenter, randomized, open study comparing once-daily fondaparinux (Arixtra^®) with adjusted-dose intravenous unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE).  J Thromb Haemost. 2003;  1(Suppl 1) OC331
• 34 Francis C W, Berkowitz S D, Comp P C et al.. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.  N Engl J Med. 2003;  349 1703-1712
• 35 Francis C W, Davidson B L, Berkowitz S D et al.. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.  Ann Intern Med. 2002;  137 648-655
• 36 Eriksson B I, Agnelli G, Cohen A T et al.. The oral direct thrombin inhibitor ximelagatran, and its subcutaneous (SC) form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism (VTE) in total hip or total knee replacement (THR or TKR): the EXPRESS study. Presented at the 44th Annual Meeting of the American Society of Hematology: December 6-10, 2002 Philadelphia, PA; (Abst 299)
• 37 Francis C W, Berkowitz S D, Comp P C et al.. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR). Presented at the 44th Annual Meeting of the American Society of Hematology: December 6-10, 2002 Philadelphia, PA; (Abst 300)
• 38 Turpie A GG, Gallus A S, Hoek J A. , for the Pentasaccharide Investigators A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.  N Engl J Med. 2001;  344 619-625
• 39 Eriksson B I, Bauer K A, Lassen M R, Turpie A G. , for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.  N Engl J Med. 2001;  345 1298-1304
• 40 Bauer K A, Eriksson B I, Lassen M R, Turpie A G. for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study . Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med. 2001;  345 1305-1310
• 41 Lassen M R, Bauer K A, Eriksson B I, Turpie A G. for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee . Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.  Lancet. 2002;  359 1715-1720
• 42 Turpie A G, Bauer K A, Eriksson B I, Lassen M R. for the PENTATHLON 2000 Study Steering Committee . Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.  Lancet. 2002;  359 1721-1726
• 43 Turpie A GG, Bauer K A, Eriksson B I, Lassen M R. , for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.  Arch Intern Med. 2002;  162 1833-1840
• 44 Turpie A GG. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration.  Thromb Haemost. 2003;  90 364-366
• 45 Eriksson B I, Lassen M R. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.  Arch Intern Med. 2003;  163 1337-1342
• 46 Lassen M, Bauer K A, Eriksson B I, Turpie A GG. Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra^®), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-Plus study.  J Thromb Haemost. 2003;  1(Suppl 1) P2052
• 47 Hull R D, Pineo G F, Stein P D et al.. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.  Ann Intern Med. 2001;  135 858-869